Markus Hollenbeck
Research Subjects
Markus Hollenbeck has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Bernd Grabensee
2 shared publicationsG. Wozniak
Knappschaftskrankenhaus Bottrop
2 shared publicationsM. Koch
Nephrologisches Zentrum Mettmann
2 shared publicationsPeter Heering
2 shared publications- Adina Voiculescu
Klinik für Nephrologie, Universitätsklinikum Düsseldorf, Moorenstrasse 5, 40225 Düsseldorf
1 shared publication B. Krumme
Deutsche Klinik für Diagnostik
1 shared publication
Latest Publications
- 9 January 2009
- Published by Springer Nature in Der Nephrologe
- Vol. 4 (1) , 42-52
Stellenwert der Sonographie bei der Entscheidungsfindung des Dialysezugangs und bei der Diagnostik der Shuntdysfunktion
- 9 January 2009
- Published by Springer Nature in Der Nephrologe
- Vol. 4 (1) , 42-52
Stellenwert der Sonographie bei der Entscheidungsfindung des Dialysezugangs und bei der Diagnostik der Shuntdysfunktion
- 27 June 2007
- Published by Springer Nature in Der Nephrologe
- Vol. 2 (4) , 242-251
Shunt, Dialyseeinleitung, Katheter
- 27 June 2007
- Published by Springer Nature in Der Nephrologe
- Vol. 2 (4) , 242-251
Shunt, Dialyseeinleitung, Katheter
- 1 May 2007
- Published by Springer Nature in Der Nephrologe
- Vol. 2 (3) , 211-222
Klinisches und apparatives Monitoring von Dialysefisteln und Prothesenshunts
- 1 May 2007
- Published by Springer Nature in Der Nephrologe
- Vol. 2 (3) , 211-222
Klinisches und apparatives Monitoring von Dialysefisteln und Prothesenshunts
- 1 August 2005
- Published by Dustri-Verlag Dr. Karl Feistle in Clinical Nephrology
- Vol. 64 (8) , 138-143
Use of LifeSite port systems for hemodialysis in German
Studies haveshown lower infection rates of port systems compared to established, transcutaneous cuffed-tunneled dialysis catheters. This was shown in otherwise quite healthy patients starting hemodialysis treatment. It is unclear to what extent these results can be applied to countries such as Germany where, unlike the US, central venous access systems are used mainly for patients with a high comorbidity. We investigated complications in patients with exhausted access sites and a high comorbidity. In a retrospective, representative multicenter study, 34 patients with a high rate of comorbidity were assessed. The age was 67.5 +/- 12.5 years, the median number of failed AV fistulas or AV grafts was 4 (0-18). The survival rate was 84.9%, 55.2% and 55.2% after 6, 12 and 24 months, respectively. The rate of local and systemic infections was 2.83 per 1,000 patient days. Thrombotic events occurred at a rate of 2.26 per 1,000 patient days. We did not see a statistically significant effect using 0.2% sodium oxychlorosene (n = 13) or 70% isopropyl alcohol solution (n = 21) as the antimicrobial solution used before opening the valve of the port with the dialysis needle. We showed that complications of hemodialysis treatment using LifeSite vascular access systems in patients with very high co-morbidity in Germany seem to occur less often than those reported for cuffed-tunneled catheters and were not more frequent than those reported for other patient groups using LifeSites in the US. Technical survival rates were encouraging for up to two years. LifeSite port systems might be a good or even better central venous access than cuffed-tunneled catheters for patients in which an AV fistula or -graft is not possible.
- 1 August 2005
- Published by Dustri-Verlag Dr. Karl Feistle in Clinical Nephrology
- Vol. 64 (8) , 138-143
Use of LifeSite port systems for hemodialysis in German
Studies haveshown lower infection rates of port systems compared to established, transcutaneous cuffed-tunneled dialysis catheters. This was shown in otherwise quite healthy patients starting hemodialysis treatment. It is unclear to what extent these results can be applied to countries such as Germany where, unlike the US, central venous access systems are used mainly for patients with a high comorbidity. We investigated complications in patients with exhausted access sites and a high comorbidity. In a retrospective, representative multicenter study, 34 patients with a high rate of comorbidity were assessed. The age was 67.5 +/- 12.5 years, the median number of failed AV fistulas or AV grafts was 4 (0-18). The survival rate was 84.9%, 55.2% and 55.2% after 6, 12 and 24 months, respectively. The rate of local and systemic infections was 2.83 per 1,000 patient days. Thrombotic events occurred at a rate of 2.26 per 1,000 patient days. We did not see a statistically significant effect using 0.2% sodium oxychlorosene (n = 13) or 70% isopropyl alcohol solution (n = 21) as the antimicrobial solution used before opening the valve of the port with the dialysis needle. We showed that complications of hemodialysis treatment using LifeSite vascular access systems in patients with very high co-morbidity in Germany seem to occur less often than those reported for cuffed-tunneled catheters and were not more frequent than those reported for other patient groups using LifeSites in the US. Technical survival rates were encouraging for up to two years. LifeSite port systems might be a good or even better central venous access than cuffed-tunneled catheters for patients in which an AV fistula or -graft is not possible.
- 1 January 1997
- Published by Taylor & Francis in Blood Pressure
- Vol. 6 (1) , 13-17
Development of Insulin Resistance and Elevated Blood Pressure during Therapy with Cyclosporine A
Essential hypertension and insulin resistance frequently coexist; cyclosporine A (CsA) is known to induce hypertension which has been used as a model for essential hypertension. The present study aimed to evaluate whether elevated blood pressure and insulin resistance coexist during CsA therapy to prove the similarity between essential hypertension and CsA induced hypertension. Normotensive patients who underwent keratoplasty were investigated before and during single therapy with CsA (2-4 mg/kg body weight) in an open A-B Trial. Eighteen lean, normotensive patients without metabolic disorders with normal renal function and without family history of hypertension or metabolic abnormalities. Insulin sensitivity index was determined by the modified frequent sampling intravenous glucose tolerance test (FSIGT) and blood pressure was determined by indirect ambulatory blood pressure monitoring. Mean insulin sensitivity index (S1) was significantly reduced (p < 0.03) during treatment with CsA (4.4 +/- 2.6 x 10(-4) vs 2.8 +/- 2.0 x 10(-4)/min per microU/ml), whereas mean systolic daytime blood pressure increased from 126.4 +/- 10.8 mmHg to 135.7 +/- 11.8 mmHg (p < 0.02), as well as the corresponding diastolic blood pressure from 76.8 +/- 8.7 mmHg to 82.8 +/- 9.3 mmHg (p < 0.05). CsA therapy induces elevated blood pressure and insulin resistance as seen in patients with essential hypertension, thus CsA induced hypertension is considered to have pathophysiological similarities to essential hypertension.
- 1 January 1997
- Published by Taylor & Francis in Blood Pressure
- Vol. 6 (1) , 13-17
Development of Insulin Resistance and Elevated Blood Pressure during Therapy with Cyclosporine A
Essential hypertension and insulin resistance frequently coexist; cyclosporine A (CsA) is known to induce hypertension which has been used as a model for essential hypertension. The present study aimed to evaluate whether elevated blood pressure and insulin resistance coexist during CsA therapy to prove the similarity between essential hypertension and CsA induced hypertension. Normotensive patients who underwent keratoplasty were investigated before and during single therapy with CsA (2-4 mg/kg body weight) in an open A-B Trial. Eighteen lean, normotensive patients without metabolic disorders with normal renal function and without family history of hypertension or metabolic abnormalities. Insulin sensitivity index was determined by the modified frequent sampling intravenous glucose tolerance test (FSIGT) and blood pressure was determined by indirect ambulatory blood pressure monitoring. Mean insulin sensitivity index (S1) was significantly reduced (p < 0.03) during treatment with CsA (4.4 +/- 2.6 x 10(-4) vs 2.8 +/- 2.0 x 10(-4)/min per microU/ml), whereas mean systolic daytime blood pressure increased from 126.4 +/- 10.8 mmHg to 135.7 +/- 11.8 mmHg (p < 0.02), as well as the corresponding diastolic blood pressure from 76.8 +/- 8.7 mmHg to 82.8 +/- 9.3 mmHg (p < 0.05). CsA therapy induces elevated blood pressure and insulin resistance as seen in patients with essential hypertension, thus CsA induced hypertension is considered to have pathophysiological similarities to essential hypertension.